Pregnancy & Lactation in Nuclear Medicine
Fetal-dose considerations, radioiodine contraindication, and breastfeeding interruption
Quick Answer
Pregnancy and lactation change both diagnostic and therapeutic radiopharmaceutical decisions. Most diagnostic studies deliver low fetal doses (well below teratogenic thresholds) and can be justified when clinically necessary, with dose-optimization and hydration/frequent voiding (the bladder is usually the largest fetal-dose source for renally-excreted tracers). Therapeutic radioiodine (I-131) is absolutely contraindicated in pregnancy — it crosses the placenta and, from ~10–12 weeks, ablates the fetal thyroid. Breastfeeding must be interrupted or stopped for agent-specific intervals because many radiopharmaceuticals are excreted in milk.
Pregnancy
- Exclude pregnancy before radionuclide administration in anyone of childbearing potential — a procedural gate, especially before any therapy (history ± β-hCG per policy).
- Diagnostic studies: generally low fetal dose (typically << 50 mGy, far below the ~100–200 mGy range associated with deterministic fetal effects). Justify, optimize activity, and encourage hydration and frequent voiding. Prefer a non-ionizing alternative (US/MRI) when it answers the question.
- Therapy: I-131 and other therapeutic radionuclides are contraindicated — defer until after delivery and after lactation has ceased. The fetal thyroid concentrates iodine from ~10–12 weeks, so I-131 can ablate it.
- Perfusion vs ventilation for suspected PE: a reduced-dose perfusion-only study is often used first in pregnancy; hydration/voiding limit bladder (fetal) dose.
Lactation
- Many agents appear in breast milk; interrupt or discontinue breastfeeding per agent and activity.
- Short-lived Tc-99m diagnostic agents typically need only a brief interruption (hours) — and some (e.g., MDP, MAG3) require none per guidance; free pertechnetate and I-123 need longer interruption.
- I-131 therapy: breastfeeding must have stopped and the breast involuted (conventionally ≥ ~6 weeks) before treatment — the lactating breast avidly concentrates iodine, delivering dose to breast tissue and, via milk, to the infant.
- After higher-activity therapy, apply close-contact restrictions with the infant/young children (cumulative external dose).
Representative Interruption Guidance
| Agent | Breastfeeding action |
|---|---|
| Tc-99m MDP, MAG3, DTPA | Usually no interruption |
| Tc-99m pertechnetate, sestamibi | Interrupt ~hours–24 h per activity |
| I-123 (diagnostic) | Interrupt ~day(s) |
| I-131 (therapy) | Stop entirely; requires prior involution |
| F-18-FDG | Short interruption + limit close infant contact (external dose) |
(Values are guidance; verify against the current agent-specific reference and regulator.)
The One Absolute, and Where the Real Dose Hides
- Absolute: therapeutic I-131 in pregnancy — placental transfer + fetal-thyroid ablation from ~10–12 weeks.
- Hidden dose: the bladder is the dominant fetal-dose contributor for renally-excreted diagnostic tracers — hydration/voiding meaningfully cut it.
Reporting / Practice Notes
- Document pregnancy exclusion and, for therapy, the written directive and counseling.
- State breastfeeding-interruption instructions specific to the agent and activity.
- Note close-contact precautions after higher-activity therapy.
Common Pitfalls
- Failing to exclude pregnancy before therapy.
- Assuming all Tc-99m agents require the same (or any) breastfeeding interruption.
- Overlooking bladder dose as the main fetal-dose source.
- Forgetting close-contact (external) dose to the infant after FDG/therapy, separate from milk excretion.
Board Pearls
Therapeutic I-131 is absolutely contraindicated in pregnancy — it crosses the placenta and, from ~10–12 weeks, ablates the fetal thyroid — and requires lactation to have ceased and the breast involuted (conventionally ≥6 weeks) before treatment. Most diagnostic studies deliver low fetal doses and can be justified when necessary, with hydration/frequent voiding, because the bladder is usually the largest fetal-dose contributor for renally-excreted tracers.
Breastfeeding-interruption times are agent- and activity-specific: short-lived Tc-99m agents often need only hours (some none), while I-131 requires lactation to have stopped entirely. The lactating breast avidly concentrates iodine — one reason involution matters before therapy.
Separate the two exposure routes: milk excretion (interrupt/stop breastfeeding) and external close-contact dose (hold/limit contact after FDG or therapy). "Declared pregnancy" also triggers additional occupational fetal-dose constraints for staff. For suspected PE in pregnancy, a reduced-dose perfusion-only study with hydration/voiding is a common first step.
Related Pages
- Tracer: Radioiodine (I-123/I-131); physics: radiation biology & protection; safety: radiation safety & patient release.
Figure / Diagram Suggestions
- A fetal-dose contributor diagram (bladder as dominant source; hydration/voiding mitigation).
- A breastfeeding-interruption ladder by agent/activity.
Self-Check
Q1. Why is therapeutic I-131 absolutely contraindicated in pregnancy?
Answer: It crosses the placenta and, from ~10–12 weeks, the fetal thyroid concentrates iodine, so I-131 can ablate it.
Q2. For a renally-excreted diagnostic tracer in a pregnant patient, what is the largest fetal-dose source and how is it reduced?
Answer: The bladder — reduced by hydration and frequent voiding.
Q3. A breastfeeding mother needs a Tc-99m MDP bone scan. What interruption is typically required?
Answer: Usually none — short-lived Tc-99m MDP generally requires no interruption (verify per current guidance); longer interruptions apply to pertechnetate/I-123 and I-131.
Q4. After FDG-PET in a nursing mother, what precaution applies beyond milk excretion?
Answer: Limit close infant contact to reduce external (photon) dose — a route separate from milk excretion.
Evidence & sources
https://nuc.med/pregnancy-lactation/ Report an issue